Ocular Therapeutix
OCUL
108 hedge funds and large institutions have $301M invested in Ocular Therapeutix in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 30 reducing their positions, and 16 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 30
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
2% more funds holding
Funds holding: 106 → 108 (+2)
1.56% more ownership
Funds ownership: 61.62% → 63.18% (+1.6%)
8% less call options, than puts
Call options by funds: $1.84M | Put options by funds: $2.01M
6% less capital invested
Capital invested by funds: $321M → $301M (-$19.2M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$11.6M |
| 2 |
BlackRock
New York
|
+$3.87M |
| 3 |
Two Sigma Advisers
New York
|
+$2.42M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.02M |
| 5 |
JP Morgan Chase
New York
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$6M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$3.43M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.82M |
| 4 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$2.6M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.23M |
OCUL Hedge Fund Activity: Q3 2020 in Review
108 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2020, worth a combined $301M — down 6% from $321M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new OCUL positions and 16 closed out — a net gain of 3 holders — while 39 added to existing stakes and 30 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $11.6M. The largest seller was Corriente Advisors, exiting entirely with an estimated $6M sold.
- 108 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2020, up from 106 in Q2 2020.
- Funds reported $301M of Ocular Therapeutix stock for Q3 2020, down 6% quarter-over-quarter.
- 19 funds opened new Ocular Therapeutix positions in Q3 2020 and 16 closed out, a net change of +3 holders.
- The largest Ocular Therapeutix buyer in Q3 2020 was Citadel Advisors, an estimated $11.6M added.
- The largest Ocular Therapeutix seller in Q3 2020 was Corriente Advisors, an estimated $6M sold.
Based on aggregated 13F filings for Q3 2020.